Pharmacogenetics and future strategies in treating hyperglycaemia in diabetes

Frontiers in Bioscience

Volumn 14, Issue 11, 2009, Pages 4348-4362

  Pearson, Ewan R ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Drug response; Metformin; Pharmacogenetics; Pharmacogenomics; Review; Sulphonylureas; Thiazolidinediones

Indexed keywords

ANTIDIABETIC AGENT;

BLOOD; DIABETES MELLITUS; HUMAN; HYPERGLYCEMIA; PHARMACOGENETICS; REVIEW;

DIABETES MELLITUS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; PHARMACOGENETICS;

EID: 63849305112     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3532     Document Type: Review

References (106)

1. Pearson, E. R., B. J. Starkey, R. J. Powell, F. M. Gribble, P. M. Clark & A. T. Hattersley: Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet, 362, 1275-81(2003) (Pubitemid 37324255)
2. Pearson, E. R., I. Flechtner, P. R. Njolstad, M. T. Malecki, S. E. Flanagan, B. Larkin, F. M. Ashcroft, I. Klimes, E. Codner, V. Iotova, A. S. Slingerland, J. Shield, J. J. Robert, J. J. Holst, P. M. Clark, S. Ellard, O. Sovik, M. Polak & A. T. Hattersley: Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med, 355, 467-77(2006) (Pubitemid 44162274)
3. Gribble, F. M. & F. Reimann: Sulphonylurea action revisited: the post-cloning era. Diabetologia, 46, 875-91(2003) (Pubitemid 36961311)
4. Simonson, D. C., I. A. Kourides, M. Feinglos, H. Shamoon & C. T. Fischette: Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care, 20, 597-606(1997) (Pubitemid 27143421)
5. Rosenstock, J., E. Samols, D. B. Muchmore & J. Schneider: Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care, 19, 1194-9(1996)
6. Groop, L. C.: Sulfonylureas in NIDDM. Diabetes Care, 15, 737-54(1992)
7. Groop, L., E. Wahlin-Boll, P. H. Groop, K. J. Totterman, A. Melander, E. M. Tolppanen & F. Fyhrqvist: Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics. Eur J Clin Pharmacol, 28, 697-704(1985) (Pubitemid 15231983)
8. De Fronzo, R. A.: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med, 131, 281-303(1999) (Pubitemid 29383658)
9. Scott, J. & P. L. Poffenbarger: Pharmacogenetics of tolbutamide metabolism in humans. Diabetes, 28, 41-51(1979) (Pubitemid 9103174)
10. Relling, M. V., T. Aoyama, F. J. Gonzalez & U. A. Meyer: Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther, 252, 442-7(1990) (Pubitemid 20067748)
11. Veronese, M. E., P. I. Mackenzie, C. J. Doecke, M. E. McManus, J. O. Miners & D. J. Birkett: Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun, 175, 1112-8(1991)
12. Kirchheiner, J., J. Brockmoller, I. Meineke, S. Bauer, W. Rohde, C. Meisel & I. Roots: Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther, 71, 286-96(2002) (Pubitemid 34311458)
13. Elliot, D. J., Suharjono, B. C. Lewis, E. M. Gillam, D. J. Birkett, A. S. Gross & J. O. Miners: Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. Br J Clin Pharmacol, 64, 450-7(2007) (Pubitemid 47404317)
14. Kidd, R. S., T. B. Curry, S. Gallagher, T. Edeki, J. Blaisdell & J. A. Goldstein: Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics, 11, 803-8(2001) (Pubitemid 33151515)
15. Rosenkranz, B.: Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. Horm Metab Res, 28, 434-9(1996) (Pubitemid 26343734)
16. Wang, R., K. Chen, S. Y. Wen, J. Li & S. Q. Wang: Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms. Clin Pharmacol Ther, 78, 90-2(2005) (Pubitemid 40956936)
17. Suzuki, K., T. Yanagawa, T. Shibasaki, N. Kaniwa, R. Hasegawa & M. Tohkin: Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract, 72, 148-54(2006)
18. Sullivan-Klose, T. H., B. I. Ghanayem, D. A. Bell, Z. Y. Zhang, L. S. Kaminsky, G. M. Shenfield, J. O. Miners, D. J. Birkett & J. A. Goldstein: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 6, 341-9(1996) (Pubitemid 26288624)
19. Ieiri, I., H. Tainaka, T. Morita, A. Hadama, K. Mamiya, M. Hayashibara, H. Ninomiya, S. Ohmori, M. Kitada, N. Tashiro, S. Higuchi & K. Otsubo: Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther Drug Monit, 22, 237-44(2000) (Pubitemid 30346437)
20. Stubbins, M. J., L. W. Harries, G. Smith, M. H. Tarbit & C. R. Wolf: Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics, 6, 429-39(1996) (Pubitemid 26380099)
21. Kirchheiner, J., S. Bauer, I. Meineke, W. Rohde, V. Prang, C. Meisel, I. Roots & J. Brockmoller: Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics, 12, 101-9(2002) (Pubitemid 34298914)
22. Babenko, A. P., M. Polak, H. Cave, K. Busiah, P. Czernichow, R. Scharfmann, J. Bryan, L. Aguilar-Bryan, M. Vaxillaire & P. Froguel: Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med, 355, 456-66(2006) (Pubitemid 44162273)
23. Ellard, S., C. Bellanne-Chantelot & A. T. Hattersley: Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia, 51, 546-53(2008)
24. Frayling, T. M., M. P. Bulamn, S. Ellard, M. Appleton, M. J. Dronsfield, A. D. Mackie, J. D. Baird, P. J. Kaisaki, K. Yamagata, G. I. Bell, S. C. Bain & A. T. Hattersley: Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the U. K. Diabetes, 46, 720-5(1997) (Pubitemid 27143394)
25. Shepherd, M., E. R. Pearson, J. Houghton, G. Salt, S. Ellard & A. T. Hattersley: No deterioration in glycemic control in HNF-1alpha maturity-onset diabetes of the young following transfer from longterm insulin to sulphonylureas. Diabetes Care, 26, 3191-2(2003) (Pubitemid 37339526)
26. Iafusco, D., M. A. Stazi, R. Cotichini, M. Cotellessa, M. E. Martinucci, M. Mazzella, V. Cherubini, F. Barbetti, M. Martinetti, F. Cerutti & F. Prisco: Permanent diabetes mellitus in the first year of life. Diabetologia, 45, 798-804(2002)
27. Edghill, E. L., R. J. Dix, S. E. Flanagan, P. J. Bingley, A. T. Hattersley, S. Ellard & K. M. Gillespie: HLA genotyping supports a nonautoimmune etiology in patients diagnosed with diabetes under the age of 6 months. Diabetes, 55, 1895-8(2006) (Pubitemid 44324150)
28. Shield, J. P.: Neonatal diabetes: how research unravelling the genetic puzzle has both widened our understanding of pancreatic development whilst improving children's quality of life. Horm Res, 67, 77-83(2007) (Pubitemid 46333775)
29. Gloyn, A. L., E. R. Pearson, J. F. Antcliff, P. Proks, G. J. Bruining, A. S. Slingerland, N. Howard, S. Srinivasan, J. M. Silva, J. Molnes, E. L. Edghill, T. M. Frayling, I. K. Temple, D. Mackay, J. P. Shield, Z. Sumnik, A. van Rhijn, J. K. Wales, P. Clark, S. Gorman, J. Aisenberg, S. Ellard, P. R. Njolstad, F. M. Ashcroft & A. T. Hattersley: Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med, 350, 1838-49(2004) (Pubitemid 38917250)
30. Proks, P., A. L. Arnold, J. Bruining, C. Girard, S. E. Flanagan, B. Larkin, K. Colclough, A. T. Hattersley, F. M. Ashcroft & S. Ellard: A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum Mol Genet, 15, 1793-800(2006) (Pubitemid 43821769)
31. Sagen, J. V., H. Raeder, E. Hathout, N. Shehadeh, K. Gudmundsson, H. Baevre, D. Abuelo, C. Phornphutkul, J. Molnes, G. I. Bell, A. L. Gloyn, A. T. Hattersley, A. Molven, O. Sovik & P. R. Njolstad: Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes, 53, 2713-8(2004) (Pubitemid 39299284)
32. Grant, S. F., G. Thorleifsson, I. Reynisdottir, R. Benediktsson, A. Manolescu, J. Sainz, A. Helgason, H. Stefansson, V. Emilsson, A. Helgadottir, U. Styrkarsdottir, K. P. Magnusson, G. B. Walters, E. Palsdottir, T. Jonsdottir, T. Gudmundsdottir, A. Gylfason, J. Saemundsdottir, R. L. Wilensky, M. P. Reilly, D. J. Rader, Y. Bagger, C. Christiansen, V. Gudnason, G. Sigurdsson, U. Thorsteinsdottir, J. R. Gulcher, A. Kong & K. Stefansson: Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet, 38, 320-3(2006)
33. Frayling, T. M.: Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet, 8, 657-62(2007) (Pubitemid 47281993)
34. Gloyn, A. L., M. N. Weedon, K. R. Owen, M. J. Turner, B. A. Knight, G. Hitman, M. Walker, J. C. Levy, M. Sampson, S. Halford, M. I. McCarthy, A. T. Hattersley & T. M. Frayling: Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes, 52, 568-72(2003) (Pubitemid 36173218)
35. Florez, J. C., N. Burtt, P. I. de Bakker, P. Almgren, T. Tuomi, J. Holmkvist, D. Gaudet, T. J. Hudson, S. F. Schaffner, M. J. Daly, J. N. Hirschhorn, L. Groop & D. Altshuler: Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes, 53, 1360-8(2004) (Pubitemid 38569024)
36. t Hart, L. M., T. W. van Haeften, J. M. Dekker, M. Bot, R. J. Heine & J. A. Maassen: Variations in insulin secretion in carriers of the E23K variant in the KIR6.2 subunit of the ATP-sensitive K (+) channel in the beta-cell. Diabetes, 51, 3135-8(2002)
37. Sesti, G., E. Laratta, M. Cardellini, F. Andreozzi, S. Del Guerra, C. Irace, A. Gnasso, M. Grupillo, R. Lauro, M. L. Hribal, F. Perticone & P. Marchetti: The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab, 91, 2334-9(2006) (Pubitemid 43855025)
38. Gloyn, A. L., Y. Hashim, S. J. Ashcroft, R. Ashfield, S. Wiltshire & R. C. Turner: Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabet Med, 18, 206-12(2001) (Pubitemid 32397858)
39. Sesti, G., M. A. Marini, M. Cardellini, A. Sciacqua, S. Frontoni, F. Andreozzi, C. Irace, D. Lauro, A. Gnasso, M. Federici, F. Perticone & R. Lauro: The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care, 27, 1394-8(2004) (Pubitemid 38679989)
40. Florez, J. C., K. A. Jablonski, S. E. Kahn, P. W. Franks, D. Dabelea, R. F. Hamman, W. C. Knowler, D. M. Nathan & D. Altshuler: Type 2 diabetesassociated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes, 56, 531-6(2007)
41. Laukkanen, O., J. Pihlajamaki, J. Lindstrom, J. Eriksson, T. T. Valle, H. Hamalainen, P. Ilanne-Parikka, S. Keinanen-Kiukaanniemi, J. Tuomilehto, M. Uusitupa & M. Laakso: Polymorphisms of the SUR1 (ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to type 2 diabetes. The Finnish Diabetes Prevention Study. J Clin Endocrinol Metab, 89, 6286-90(2004) (Pubitemid 39628447)
42. Saxena, R., L. Gianniny, N. P. Burtt, V. Lyssenko, C. Giuducci, M. Sjogren, J. C. Florez, P. Almgren, B. Isomaa, M. Orho-Melander, U. Lindblad, M. J. Daly, T. Tuomi, J. N. Hirschhorn, K. G. Ardlie, L. C. Groop & D. Altshuler: Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes, 55, 2890-5(2006) (Pubitemid 44923692)
43. Lyssenko, V., R. Lupi, P. Marchetti, S. Del Guerra, M. Orho-Melander, P. Almgren, M. Sjogren, C. Ling, K. F. Eriksson, A. L. Lethagen, R. Mancarella, G. Berglund, T. Tuomi, P. Nilsson, S. Del Prato & L. Groop: Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest, 117, 2155-63(2007) (Pubitemid 47219560)
44. Pearson, E. R., L. A. Donnelly, C. Kimber, A. Whitley, A. S. Doney, M. I. McCarthy, A. T. Hattersley, A. D. Morris & C. N. Palmer: Variation in TCF7L2 influences therapeutic response to sulfonylureas: A GoDARTs study. Diabetes, 56, 2178-2182(2007) (Pubitemid 47195841)
45. Natali, A. & E. Ferrannini: Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia, 49, 434-41(2006) (Pubitemid 43277865)
46. Basu, R., P. Shah, A. Basu, B. Norby, B. Dicke, V. Chandramouli, O. Cohen, B. R. Landau & R. A. Rizza: Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes. Diabetes, 57, 24-31(2008)
47. Zhou, G., R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M. F. Hirshman, L. J. Goodyear & D. E. Moller: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 108, 1167-74(2001) (Pubitemid 32995375)
48. Shaw, R. J., K. A. Lamia, D. Vasquez, S. H. Koo, N. Bardeesy, R. A. Depinho, M. Montminy & L. C. Cantley: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 310, 1642-6(2005) (Pubitemid 41780780)
49. Hardie, D. G.: Neither LKB1 nor AMPK are the direct targets of metformin. Gastroenterology, 131, 973; author reply 974-5 (2006) (Pubitemid 44307086)
50. Owen, M. R., E. Doran & A. P. Halestrap: Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J, 348 Pt 3, 607-14(2000) (Pubitemid 30410251)
51. Nathan, D. M., J. B. Buse, M. B. Davidson, R. J. Heine, R. R. Holman, R. Sherwin & B. Zinman: Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 29, 1963-72(2006) (Pubitemid 44156663)
52. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352, 854-65(1998)
53. Hermann, L. S., B. Schersten, P. O. Bitzen, T. Kjellstrom, F. Lindgarde & A. Melander: Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care, 17, 1100-9(1994) (Pubitemid 24307443)
54. Johansen, K.: Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care, 22, 33-7(1999) (Pubitemid 29028295)
55. Klip, A. & L. A. Leiter: Cellular mechanism of action of metformin. Diabetes Care, 13, 696-704(1990) (Pubitemid 20169149)
56. Tucker, G. T., C. Casey, P. J. Phillips, H. Connor, J. D. Ward & H. F. Woods: Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol, 12, 235-46(1981) (Pubitemid 11034446)
57. Scheen, A. J.: Clinical pharmacokinetics of metformin. Clin Pharmacokinet, 30, 359-71(1996) (Pubitemid 26177181)
58. Vidon, N., S. Chaussade, M. Noel, C. Franchisseur, B. Huchet & J. J. Bernier: Metformin in the digestive tract. Diabetes Res Clin Pract, 4, 223-9(1988) (Pubitemid 18080749)
59. Proctor, W. R., D. L. Bourdet & D. R. Thakker: Mechanisms Underlying Saturable Intestinal Absorption of Metformin. Drug Metab Dispos (2008)
60. Zhou, M., L. Xia & J. Wang: Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos, 35, 1956-62(2007) (Pubitemid 47481592)
61. Wang, D. S., J. W. Jonker, Y. Kato, H. Kusuhara, A. H. Schinkel & Y. Sugiyama: Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther, 302, 510-5(2002) (Pubitemid 34787213)
62. Kimura, N., S. Masuda, Y. Tanihara, H. Ueo, M. Okuda, T. Katsura & K. Inui: Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet, 20, 379-86(2005)
63. Otsuka, M., T. Matsumoto, R. Morimoto, S. Arioka, H. Omote & Y. Moriyama: A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A, 102, 17923-8(2005) (Pubitemid 41798478)
64. Tanihara, Y., S. Masuda, T. Sato, T. Katsura, O. Ogawa & K. Inui: Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H (+)-organic cation antiporters. Biochem Pharmacol, 74, 359-71(2007) (Pubitemid 46890818)
65. Kerb, R., U. Brinkmann, N. Chatskaia, D. Gorbunov, V. Gorboulev, E. Mornhinweg, A. Keil, M. Eichelbaum & H. Koepsell: Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics, 12, 591-5(2002) (Pubitemid 36005667)
66. Shu, Y., M. K. Leabman, B. Feng, L. M. Mangravite, C. C. Huang, D. Stryke, M. Kawamoto, S. J. Johns, J. De Young, E. Carlson, T. E. Ferrin, I. Herskowitz & K. M. Giacomini: Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A, 100, 5902-7(2003) (Pubitemid 36576905)
67. Shu, Y., S. A. Sheardown, C. Brown, R. P. Owen, S. Zhang, R. A. Castro, A. G. Ianculescu, L. Yue, J. C. Lo, E. G. Burchard, C. M. Brett & K. M. Giacomini: Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest, 117, 1422-31(2007) (Pubitemid 46718430)
68. Itoda, M., Y. Saito, K. Maekawa, H. Hichiya, K. Komamura, S. Kamakura, M. Kitakaze, H. Tomoike, K. Ueno, S. Ozawa & J. Sawada: Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug Metab Pharmacokinet, 19, 308-12(2004)
69. Sakata, T., N. Anzai, H. J. Shin, R. Noshiro, T. Hirata, H. Yokoyama, Y. Kanai & H. Endou: Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun, 313, 789-93(2004) (Pubitemid 38021900)
70. Wang, D. S., H. Kusuhara, Y. Kato, J. W. Jonker, A. H. Schinkel & Y. Sugiyama: Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol, 63, 844-8(2003) (Pubitemid 36368991)
71. Shu, Y., C. Brown, R. A. Castro, R. J. Shi, E. T. Lin, R. P. Owen, S. A. Sheardown, L. Yue, E. G. Burchard, C. M. Brett & K. M. Giacomini: Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther, 83, 273-80(2008)
72. Leabman, M. K., C. C. Huang, M. Kawamoto, S. J. Johns, D. Stryke, T. E. Ferrin, J. De Young, T. Taylor, A. G. Clark, I. Herskowitz & K. M. Giacomini: Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics, 12, 395-405(2002) (Pubitemid 34816419)
73. Saito, S., A. Iida, A. Sekine, C. Ogawa, S. Kawauchi, S. Higuchi & Y. Nakamura: Catalog of 238 variations among six human genes encoding solute carriers (hSLCs) in the Japanese population. J Hum Genet, 47, 576-84(2002) (Pubitemid 36083257)
74. Fukushima-Uesaka, H., K. Maekawa, S. Ozawa, K. Komamura, K. Ueno, M. Shibakawa, S. Kamakura, M. Kitakaze, H. Tomoike, Y. Saito & J. Sawada: Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2) Drug Metab Pharmacokinet, 19, 239-44(2004)
75. Kang, H. J., I. S. Song, H. J. Shin, W. Y. Kim, C. H. Lee, J. C. Shim, H. H. Zhou, S. S. Lee & J. G. Shin: Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metab Dispos, 35, 667-75(2007)
76. Song, I., H. Shin, E. Shim, I. Jung, W. Kim, J. Shon & J. Shin: Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin. Clin Pharmacol Ther (2008)
77. Donnelly, L. A., A. S. Doney, A. T. Hattersley, A. D. Morris & E. R. Pearson: The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes. Diabet Med, 23, 128-33(2006)
78. Horikoshi, M., K. Hara, J. Ohashi, K. Miyake, K. Tokunaga, C. Ito, M. Kasuga, R. Nagai & T. Kadowaki: A polymorphism in the AMPKalpha2 subunit gene is associated with insulin resistance and type 2 diabetes in the Japanese population. Diabetes, 55, 919-23(2006) (Pubitemid 44100164)
79. Yki-Jarvinen, H.: Thiazolidinediones. N Engl J Med, 351, 1106-18(2004)
80. LeBrasseur, N. K., M. Kelly, T. S. Tsao, S. R. Farmer, A. K. Saha, N. B. Ruderman & E. Tomas: Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab, 291, E175-81 (2006) (Pubitemid 44035323)
81. Boyle, J. G., P. J. Logan, M. A. Ewart, J. A. Reihill, S. A. Ritchie, J. M. Connell, S. J. Cleland & I. P. Salt: Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase. J Biol Chem, 283, 11210-7(2008)
82. Rosenstock, J., D. Sugimoto, P. Strange, J. A. Stewart, E. Soltes-Rak & G. Dailey: Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care, 29, 554-9(2006) (Pubitemid 44115353)
83. Rosenstock, J., B. J. Goldstein, A. I. Vinik, C. O'Neill M, L. E. Porter, M. A. Heise, B. Kravitz, R. G. Dirani & M. I. Freed: Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes Obes Metab, 8, 49-57(2006)
84. Kahn, S. E., S. M. Haffner, M. A. Heise, W. H. Herman, R. R. Holman, N. P. Jones, B. G. Kravitz, J. M. Lachin, M. C. O'Neill, B. Zinman & G. Viberti: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med, 355, 2427-43(2006) (Pubitemid 44903747)
85. Snitker, S., R. M. Watanabe, I. Ani, A. H. Xiang, A. Marroquin, C. Ochoa, J. Goico, A. R. Shuldiner & T. A. Buchanan: Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptorgamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care, 27, 1365-8(2004) (Pubitemid 38679984)
86. Cox, P. J., D. A. Ryan, F. J. Hollis, A. M. Harris, A. K. Miller, M. Vousden & H. Cowley: Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos, 28, 772-80(2000) (Pubitemid 30470827)
87. Baldwin, S. J., S. E. Clarke & R. J. Chenery: Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol, 48, 424-32(1999) (Pubitemid 29417728)
88. Budde, K., H. H. Neumayer, L. Fritsche, W. Sulowicz, T. Stompor & D. Eckland: The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol, 55, 368-74(2003) (Pubitemid 36535367)
89. Jaakkola, T., J. T. Backman, M. Neuvonen, J. Laitila & P. J. Neuvonen: Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol, 61, 70-8(2006) (Pubitemid 43381239)
90. Kirchheiner, J., S. Thomas, S. Bauer, D. Tomalik-Scharte, U. Hering, O. Doroshyenko, A. Jetter, S. Stehle, M. Tsahuridu, I. Meineke, J. Brockmoller & U. Fuhr: Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther, 80, 657-67(2006) (Pubitemid 44920222)
91. *3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos, 36, 73-80(2008)
92. Altshuler, D., J. N. Hirschhorn, M. Klannemark, C. M. Lindgren, M. C. Vohl, J. Nemesh, C. R. Lane, S. F. Schaffner, S. Bolk, C. Brewer, T. Tuomi, D. Gaudet, T. J. Hudson, M. Daly, L. Groop & E. S. Lander: The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet, 26, 76-80(2000)
93. Muller, Y. L., C. Bogardus, B. A. Beamer, A. R. Shuldiner & L. J. Baier: A functional variant in the peroxisome proliferator-activated receptor gamma2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians. Diabetes, 52, 1864-71(2003) (Pubitemid 36792480)
94. Bluher, M., G. Lubben & R. Paschke: Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care, 26, 825-31(2003) (Pubitemid 36929350)
95. Wolford, J. K., K. A. Yeatts, S. K. Dhanjal, M. H. Black, A. H. Xiang, T. A. Buchanan & R. M. Watanabe: Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes, 54, 3319-25(2005) (Pubitemid 43334389)
96. Kang, E. S., S. Y. Park, H. J. Kim, C. S. Kim, C. W. Ahn, B. S. Cha, S. K. Lim, C. M. Nam & H. C. Lee: Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther, 78, 202-8(2005)
97. Kang, E. S., S. Y. Park, H. J. Kim, C. W. Ahn, M. Nam, B. S. Cha, S. K. Lim, K. R. Kim & H. C. Lee: The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care, 28, 1139-44(2005) (Pubitemid 40616625)
98. Sun, H., Z. C. Gong, J. Y. Yin, H. L. Liu, Y. Z. Liu, Z. W. Guo, H. H. Zhou, J. Wu & Z. Q. Liu: The association of adiponectin allele 45T/G and - 11377C/G polymorphisms with Type 2 diabetes and rosiglitazone response in Chinese patients. Br J Clin Pharmacol, 65, 917-26(2008) (Pubitemid 351677438)
99. Brunham, L. R., J. K. Kruit, T. D. Pape, J. M. Timmins, A. Q. Reuwer, Z. Vasanji, B. J. Marsh, B. Rodrigues, J. D. Johnson, J. S. Parks, C. B. Verchere & M. R. Hayden: Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med, 13, 340-7(2007) (Pubitemid 46376682)
100. Wang, J., Y. Q. Bao, C. Hu, R. Zhang, C. R. Wang, J. X. Lu, W. P. Jia & K. S. Xiang: Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients. Acta Pharmacol Sin, 29, 252-8(2008) (Pubitemid 351178431)
101. Singh, S., Y. K. Loke & C. D. Furberg: Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care, 30, 2148-53(2007) (Pubitemid 47219440)
102. Guan, Y., C. Hao, D. R. Cha, R. Rao, W. Lu, D. E. Kohan, M. A. Magnuson, R. Redha, Y. Zhang & M. D. Breyer: Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med, 11, 861-6(2005) (Pubitemid 41161118)
103. Zhang, H., A. Zhang, D. E. Kohan, R. D. Nelson, F. J. Gonzalez & T. Yang: Collecting ductspecific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A, 102, 9406-11(2005) (Pubitemid 40923576)
104. Spraggs, C., A. McCarthy, L. McCarthy, G. Hong, A. Hughes, X. Lin, G. Sathe, D. Smart, C. Traini, S. Van Horn, L. Warren & M. Mosteller: Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar. Pharmacogenet Genomics, 17, 1065-76(2007) (Pubitemid 351339491)
105. Hansen, L., C. T. Ekstrom, Y. P. R. Tabanera, M. Anant, K. Wassermann & R. R. Reinhardt: The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptorgamma/alpha agonist-induced edema in type 2 diabetic patients. J Clin Endocrinol Metab, 91, 3446-50(2006) (Pubitemid 44402117)
106. Weedon, M. N., M. I. McCarthy, G. Hitman, M. Walker, C. J. Groves, E. Zeggini, N. W. Rayner, B. Shields, K. R. Owen, A. T. Hattersley & T. M. Frayling: Combining information from common type 2 diabetes risk polymorphisms improves disease prediction. PLoS Med, 3, e374 (2006)